Naples Global Advisors LLC boosted its stake in CVS Health Corporation (NYSE:CVS) by 36.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,845 shares of the pharmacy operator’s stock after acquiring an additional 2,090 shares during the period. Naples Global Advisors LLC’s holdings in CVS Health Corporation were worth $631,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Mercer Capital Advisers Inc. purchased a new position in CVS Health Corporation during the first quarter worth about $118,000. Gemmer Asset Management LLC grew its position in CVS Health Corporation by 15.3% during the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after buying an additional 200 shares during the period. TB Alternative Assets Ltd. acquired a new position in CVS Health Corporation during the second quarter worth about $121,000. SRS Capital Advisors Inc. grew its position in CVS Health Corporation by 48.2% during the first quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock worth $177,000 after buying an additional 734 shares during the period. Finally, Nadler Financial Group Inc. acquired a new position in CVS Health Corporation during the second quarter worth about $202,000. 81.55% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/naples-global-advisors-llc-buys-2090-shares-of-cvs-health-corporation-cvs/1605336.html.
In related news, EVP Thomas M. Moriarty sold 90,267 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the transaction, the executive vice president now directly owns 70,102 shares in the company, valued at approximately $5,580,820.22. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard J. Swift sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $79.62, for a total value of $199,050.00. Following the transaction, the director now owns 3,258 shares in the company, valued at $259,401.96. The disclosure for this sale can be found here. Insiders have sold a total of 370,510 shares of company stock worth $29,460,266 in the last three months. 0.61% of the stock is currently owned by insiders.
Shares of CVS Health Corporation (NYSE CVS) traded up 0.41% on Friday, reaching $82.98. 5,096,623 shares of the company were exchanged. The stock has a market capitalization of $84.35 billion, a P/E ratio of 16.53 and a beta of 0.92. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $90.85. The stock has a 50 day moving average price of $78.80 and a 200-day moving average price of $78.96.
CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.02. The company had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.36 billion. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 EPS. On average, equities analysts expect that CVS Health Corporation will post $5.88 EPS for the current fiscal year.
Several research firms have recently commented on CVS. Jefferies Group LLC increased their price target on shares of CVS Health Corporation from $82.00 to $86.00 and gave the company a “hold” rating in a research report on Friday. Needham & Company LLC assumed coverage on shares of CVS Health Corporation in a research report on Tuesday, June 27th. They set a “hold” rating on the stock. Guggenheim restated a “buy” rating on shares of CVS Health Corporation in a research report on Monday, July 3rd. Leerink Swann set a $90.00 price target on shares of CVS Health Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Finally, BidaskClub raised shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $90.35.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with our FREE daily email newsletter.